


# High Performance Clustering and Discrimination in Microarray Bioinformatics

P. Bhamidipati, A. Baras (Georgetown Un.)/B. Frankpitt (AIMS, Inc.), J. Baras

## Gene Microarrays

- High-throughput experimental techniques that detect the expression of thousands of genes in a tissue simultaneously.
- DNA complementary to genes of interest are laid out in microscopic quantities at a specific location on an array and hybridized with mRNA from an experiment.
- Presence of DNA is detected by fluorescence following laser excitation.
- Applications:
  - Identification of functions for newly discovered sequences.
  - Drug discovery and toxicology.
  - Mutation or single nucleotide polymorphism(SNP) detection.




## Expression Analysis

- Objectives:
  - Compare supervised classification with LBG/LVQ and SVMs (CLUSTER).
  - Compare the performance of the new unnormalized distance (AIMS patent pending) and log-Euclidean distances in **similarity-based** techniques with oligonucleotide arrays (**FIND\_SIMILAR**).
  - Evaluate the performance of **similarity measures** in retrieving informative instances (**FIND\_DISCRIMINATING**).
- Two types of experiments are studied:
  - Gene functional classification
  - Tissue-type/Phenotype classification
- Similarity Measures:
  - Log-Euclidean distance
  - New unnormalized distance (AIMS patent pending)


## Modern Drug Discovery

- Four main phases
  - Target identification and validation
  - Compound identification and validation
  - Pre-clinical testing
  - Clinical Trials
- Impact of genomic technologies**
  - Knowledge of gene sequence → Increased number of feasible targets: receptors to genes in the transcriptional mechanism in cancerous cells.
  - Genome-wide experiments → Reduced turn-around time, *in vitro* toxicity testing.
  - Genotype analysis – correlation between chromosomal regions and traits.

## System Architecture (AIMS)



## User Interface (AIMS)



## Project Goal:

Develop IT Infrastructure for biologists working with gene expression microarray data in large organizations.

### Gene Expression Microarrays:

- Measures the concentration of mRNA molecules in small tissue samples.
- Expression levels for  $\sim 10^4$  genes in a single assay.
- Biologists infer hypotheses about the regulation and structure of cell biochemistry from patterns in microarray data.

## Tissue-type Classification

- Lymphoma Tissue-type Classification
  - Cancer Tissue Data Distribution (96 arrays & 4026 genes)
 

|                  | DLBCL | GCB | NLT | APB | RAT | TCL | FL | RPB | CLL |
|------------------|-------|-----|-----|-----|-----|-----|----|-----|-----|
| # Arrays         | 46    | 2   | 2   | 10  | 6   | 6   | 9  | 4   | 11  |
| Cancerous Tissue | Y     | N   | N   | N   | N   | Y   | Y  | N   | Y   |
  - Methods compared with 10-fold cross-validation:
    - C4.5 (Quinlan) Decision Tree – univariate implementation, continuous-valued attributes.
    - SVM with a linear kernel.
    - LBG/LVQ with log-Euclidean Distance.
  - Tests run:
    - Binary Classification (Cancer Detection)
    - Cancer Tissue Classification
  - Performance measure =  $\frac{fp + fn}{N_S}$

## Results – Lymphoma Data

- Removing 218 known lymphoma genes does not affect the algorithm performance.
- The C4.5 decision tree performance, indicating that the cancer mechanism, which causes mutations in several genes can not be clustered with simple univariate, attribute-based rules.
- SVM outperforms log-Euclidean LVQ in binary phenotype classification, and in two types of cancer tissues.

|                    | LVQ    | SVM    | C4.5    |
|--------------------|--------|--------|---------|
| Average Error Rate | 8.333% | 1.000% | 18.333% |

|                    | LVQ   | SVM   | C4.5   |
|--------------------|-------|-------|--------|
| Average Error Rate | 9.72% | 4.17% | 29.17% |

